论文部分内容阅读
从20世纪80年代以来,随着耐药结核病(尤其是耐多药结核病)发病率的不断上升以及结核病与HIV/AIDS并发导致的结核病疫情再度上升,成为全球重大公共卫生问题和社会问题。然而,近40余年来几乎没有新作用机制的抗TB药物问世,目前临床上使用的传统抗结核药物联合治疗方案虽然可使85%以上的初治肺结核患者痊愈,但多存在不良反应、药物相互作用、疗程长、对耐多药结核病无效和对潜伏态的结核杆菌作用不强等缺点,因此研发抗结核新药,实现对结核病的有效治疗与控制迫在眉睫。本文从作用机制和潜在的临床应用价值等方面对某些兼具抗结核作用的已知抗菌类药物[如氟喹诺酮类(左氧氟沙星、莫西沙星和加替沙星)和u001a唑烷酮类(利奈唑胺和PNU-100480)]以及新型抗结核化合物[如二芳基喹诺酮(R207910)、硝基咪唑并吡喃(PA-824和OPC-67683)、乙胺丁醇类似物(SQ109)、浅蓝菌素、反式肉桂酸、大环内酯类、吡咯类化合物(LL3858)、长效利福霉素和吸入性γ-干扰素]等的研究进展进行了比较全面的综述。
Since the 1980s, with the rising incidence of drug-resistant TB (especially MDR-TB) and the relapse of tuberculosis caused by the concurrent tuberculosis and HIV / AIDS, it has become a major public health and social problem in the world. However, nearly 40 years of anti-TB drugs with almost no new mechanism of action come out. Although the combination of traditional anti-tuberculosis drugs currently used in clinical practice can cure more than 85% of newly diagnosed tuberculosis patients, many adverse reactions occur. Drug interactions Therefore, it is urgent to develop new anti-tuberculosis drugs to achieve effective treatment and control of tuberculosis. This article from the mechanism of action and the potential value of clinical application of some of the known anti-tuberculosis effect of antibacterial drugs [such as fluoroquinolones (levofloxacin, moxifloxacin and gatifloxacin) and u001a oxazolidinones (Linezolid and PNU-100480)] and novel anti-TB compounds [such as diarylquinolones (R207910), nitroimidazopyran (PA-824 and OPC-67683), ethambutol analogs (SQ109) , Cerulenin, trans-cinnamic acid, macrolides, azole compounds (LL3858), long-acting rifamycins and inhaled interferon-γ] were reviewed.